Do analysts rate CNTX or ZSQR?

Context Therapeutics currently has a consensus target price of $6.60, indicating a potential upside of 676.47%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer CNTX or ZSQR?

In the previous week, Context Therapeutics and Context Therapeutics both had 3 articles in the media. Context Therapeutics' average media sentiment score of 0.93 beat Coeptis Therapeutics' score of 0.62 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, TECX or CNTX?

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tectonic Therapeutic N/A N/A -$74.15M -$4.46 N/A Context Therapeutics N/A N/A -$36.12M -$0.42 N/A

Is TECX or CNTX more profitable?

Tectonic Therapeutic's return on equity of -32.33% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -32.33% -30.92% Context Therapeutics N/A -59.95% -54.78%

Does the media refer more to TECX or CNTX?

In the previous week, Context Therapeutics had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 3 mentions for Context Therapeutics and 2 mentions for Tectonic Therapeutic. Context Therapeutics' average media sentiment score of 0.93 beat Tectonic Therapeutic's score of 0.62 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRME or CNTX?

In the previous week, Prime Medicine had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 7 mentions for Prime Medicine and 3 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.93 beat Prime Medicine's score of 0.60 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prime Medicine 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNA or CNTX?

In the previous week, Context Therapeutics had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Context Therapeutics and 2 mentions for Ginkgo Bioworks. Context Therapeutics' average media sentiment score of 0.93 beat Ginkgo Bioworks' score of 0.55 indicating that Context Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ginkgo Bioworks 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CNTX or ALT?

In the previous week, Altimmune had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Altimmune and 3 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.93 beat Altimmune's score of 0.46 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Altimmune 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Context Therapeutics (CNTX) Competitors

$0.85 -0.54 (-38.85%)

As of 10:20 AM Eastern

Compare

CNTX vs. ZSQR, TECX, PRME, DNA, and ALT

Should you buy Context Therapeutics stock or one of its competitors? MarketBeat compares Context Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Context Therapeutics include Coeptis Therapeutics (ZSQR), Tectonic Therapeutic (TECX), Prime Medicine (PRME), Ginkgo Bioworks (DNA), and Altimmune (ALT). These companies are all part of the "pharmaceutical products" industry.

How does Context Therapeutics compare to Coeptis Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and Coeptis Therapeutics (NASDAQ:ZSQR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Context Therapeutics and Context Therapeutics both had 3 articles in the media. Context Therapeutics' average media sentiment score of 0.93 beat Coeptis Therapeutics' score of 0.62 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Context Therapeutics currently has a consensus target price of $6.60, indicating a potential upside of 676.47%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Context Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 24.3% of Coeptis Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Context Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market. Comparatively, Coeptis Therapeutics has a beta of -0.22, suggesting that its stock price is 122% less volatile than the broader market.

Context Therapeutics has a net margin of 0.00% compared to Coeptis Therapeutics' net margin of -810.04%. Context Therapeutics' return on equity of -59.95% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%

Coeptis Therapeutics has higher revenue and earnings than Context Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Coeptis Therapeutics	$1.36M	432.62	-$11.92M	-$2.52	N/A

Summary

Context Therapeutics beats Coeptis Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Context Therapeutics compare to Tectonic Therapeutic?

Tectonic Therapeutic (NASDAQ:TECX) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Context Therapeutics had 1 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 3 mentions for Context Therapeutics and 2 mentions for Tectonic Therapeutic. Context Therapeutics' average media sentiment score of 0.93 beat Tectonic Therapeutic's score of 0.62 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.46	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

Tectonic Therapeutic's return on equity of -32.33% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-32.33%	-30.92%
Context Therapeutics	N/A	-59.95%	-54.78%

Tectonic Therapeutic has a beta of 3.19, indicating that its stock price is 219% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Tectonic Therapeutic currently has a consensus target price of $79.40, suggesting a potential upside of 162.96%. Context Therapeutics has a consensus target price of $6.60, suggesting a potential upside of 676.47%. Given Context Therapeutics' higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Tectonic Therapeutic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	3.00
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Tectonic Therapeutic and Context Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Context Therapeutics compare to Prime Medicine?

Prime Medicine (NASDAQ:PRME) and Context Therapeutics (NASDAQ:CNTX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

In the previous week, Prime Medicine had 4 more articles in the media than Context Therapeutics. MarketBeat recorded 7 mentions for Prime Medicine and 3 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.93 beat Prime Medicine's score of 0.60 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prime Medicine	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

70.4% of Prime Medicine shares are owned by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are owned by institutional investors. 16.0% of Prime Medicine shares are owned by insiders. Comparatively, 4.8% of Context Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Prime Medicine currently has a consensus target price of $7.65, suggesting a potential upside of 159.85%. Context Therapeutics has a consensus target price of $6.60, suggesting a potential upside of 676.47%. Given Context Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Context Therapeutics is more favorable than Prime Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prime Medicine	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Context Therapeutics has a net margin of 0.00% compared to Prime Medicine's net margin of -4,917.55%. Context Therapeutics' return on equity of -59.95% beat Prime Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prime Medicine	-4,917.55%	-188.82%	-60.97%
Context Therapeutics	N/A	-59.95%	-54.78%

Prime Medicine has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the broader market.

Context Therapeutics has lower revenue, but higher earnings than Prime Medicine. Prime Medicine is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prime Medicine	$4.63M	114.85	-$201.14M	-$1.23	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

Summary

Context Therapeutics beats Prime Medicine on 10 of the 15 factors compared between the two stocks.

How does Context Therapeutics compare to Ginkgo Bioworks?

Ginkgo Bioworks (NYSE:DNA) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

78.6% of Ginkgo Bioworks shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 12.7% of Ginkgo Bioworks shares are held by insiders. Comparatively, 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ginkgo Bioworks has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

In the previous week, Context Therapeutics had 1 more articles in the media than Ginkgo Bioworks. MarketBeat recorded 3 mentions for Context Therapeutics and 2 mentions for Ginkgo Bioworks. Context Therapeutics' average media sentiment score of 0.93 beat Ginkgo Bioworks' score of 0.55 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ginkgo Bioworks	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ginkgo Bioworks currently has a consensus target price of $8.50, suggesting a potential upside of 4.17%. Context Therapeutics has a consensus target price of $6.60, suggesting a potential upside of 676.47%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Context Therapeutics is more favorable than Ginkgo Bioworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ginkgo Bioworks	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Context Therapeutics has a net margin of 0.00% compared to Ginkgo Bioworks' net margin of -215.41%. Ginkgo Bioworks' return on equity of -56.08% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ginkgo Bioworks	-215.41%	-56.08%	-26.06%
Context Therapeutics	N/A	-59.95%	-54.78%

Context Therapeutics has lower revenue, but higher earnings than Ginkgo Bioworks. Context Therapeutics is trading at a lower price-to-earnings ratio than Ginkgo Bioworks, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ginkgo Bioworks	$170.15M	3.13	-$312.76M	-$5.36	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

Summary

Context Therapeutics beats Ginkgo Bioworks on 9 of the 16 factors compared between the two stocks.

How does Context Therapeutics compare to Altimmune?

Context Therapeutics (NASDAQ:CNTX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

Context Therapeutics has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A
Altimmune	$40K	12,859.33	-$88.09M	-$0.93	N/A

Context Therapeutics has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

14.0% of Context Therapeutics shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 4.8% of Context Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Context Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-59.95%	-54.78%
Altimmune	-214,860.98%	-42.57%	-35.57%

In the previous week, Altimmune had 2 more articles in the media than Context Therapeutics. MarketBeat recorded 5 mentions for Altimmune and 3 mentions for Context Therapeutics. Context Therapeutics' average media sentiment score of 0.93 beat Altimmune's score of 0.46 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Altimmune	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics presently has a consensus price target of $6.60, indicating a potential upside of 676.47%. Altimmune has a consensus price target of $16.67, indicating a potential upside of 530.12%. Given Context Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Context Therapeutics is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Context Therapeutics beats Altimmune on 10 of the 16 factors compared between the two stocks.

Get Context Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNTX vs. The Competition

Export

Metric	Context Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$78.47M	$2.99B	$6.49B	$12.31B
Dividend Yield	N/A	1.76%	2.67%	5.66%
P/E Ratio	-2.03	18.81	24.05	24.76
Price / Sales	N/A	468.63	542.61	168.32
Price / Cash	N/A	55.88	27.48	37.92
Price / Book	1.29	4.01	10.69	6.90
Net Income	-$36.12M	$75.79M	$3.57B	$337.45M
7 Day Performance	-50.29%	2.78%	1.56%	2.84%
1 Month Performance	-60.65%	0.52%	2.49%	4.78%
1 Year Performance	35.05%	24.68%	26.51%	33.08%

Context Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNTX Context Therapeutics	3.1597 of 5 stars	$0.85 -38.8%	$6.60 +676.5%	+120.8%	$78.47M	N/A	N/A	7	High Trading Volume
ZSQR Coeptis Therapeutics	0.301 of 5 stars	$10.52 +4.4%	N/A	+30.7%	$541.04M	$1.36M	N/A	2	Analyst Downgrade Gap Down
TECX Tectonic Therapeutic	3.0994 of 5 stars	$28.00 -3.8%	$79.40 +183.6%	+38.3%	$528.38M	N/A	N/A	120
PRME Prime Medicine	2.0762 of 5 stars	$2.87 -3.2%	$7.65 +167.0%	N/A	$517.11M	$4.03M	N/A	N/A	News Coverage Gap Up
DNA Ginkgo Bioworks	0.6397 of 5 stars	$7.89 -2.5%	$8.50 +7.7%	-11.9%	$516.68M	$170.15M	N/A	640	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNTX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Context Therapeutics (CNTX) Competitors

CNTX vs. ZSQR, TECX, PRME, DNA, and ALT

How does Context Therapeutics compare to Coeptis Therapeutics?

Summary

How does Context Therapeutics compare to Tectonic Therapeutic?

Summary

How does Context Therapeutics compare to Prime Medicine?

Summary

How does Context Therapeutics compare to Ginkgo Bioworks?

Summary

How does Context Therapeutics compare to Altimmune?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Context Therapeutics (CNTX) Competitors

CNTX vs. ZSQR, TECX, PRME, DNA, and ALT

How does Context Therapeutics compare to Coeptis Therapeutics?

Does the media prefer CNTX or ZSQR?

Do analysts rate CNTX or ZSQR?

Do insiders & institutionals believe in CNTX or ZSQR?

Which has more risk & volatility, CNTX or ZSQR?

Is CNTX or ZSQR more profitable?

Which has higher earnings & valuation, CNTX or ZSQR?

Summary

How does Context Therapeutics compare to Tectonic Therapeutic?

Does the media refer more to TECX or CNTX?

Do insiders and institutionals have more ownership in TECX or CNTX?

Which has higher valuation and earnings, TECX or CNTX?

Is TECX or CNTX more profitable?

Which has more risk and volatility, TECX or CNTX?

Do analysts recommend TECX or CNTX?

Summary

How does Context Therapeutics compare to Prime Medicine?

Does the media refer more to PRME or CNTX?

Do insiders and institutionals have more ownership in PRME or CNTX?

Do analysts recommend PRME or CNTX?

Is PRME or CNTX more profitable?

Which has more risk and volatility, PRME or CNTX?

Which has higher valuation and earnings, PRME or CNTX?

Summary

How does Context Therapeutics compare to Ginkgo Bioworks?

Do institutionals and insiders hold more shares of DNA or CNTX?

Which has more risk and volatility, DNA or CNTX?

Does the media favor DNA or CNTX?

Do analysts rate DNA or CNTX?

Is DNA or CNTX more profitable?

Which has preferable earnings & valuation, DNA or CNTX?

Summary

How does Context Therapeutics compare to Altimmune?

Which has preferable valuation & earnings, CNTX or ALT?

Which has more volatility and risk, CNTX or ALT?

Do insiders & institutionals have more ownership in CNTX or ALT?

Is CNTX or ALT more profitable?

Does the media refer more to CNTX or ALT?

Do analysts prefer CNTX or ALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNTX vs. The Competition

Context Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools